Replies to post #19428 on Radient Pharmaceuticals Corporation fka RXPC

[lakeshore555]

RXPC merger will never happen.

It's this simple: nobody is going to merge with or take over Radient because Radient is buried in debt and has only one marketable product (DR-70). Any entity wishing to manufacture and/or sell that product can simply license it from Radient the way UNI did and the way GCDx would do if they could convince an investor to fund the project.

No reason to believe "big news" or ANY news is coming soon, or ever, with the following exception: There could be a news release by Rosen when the class action is finalized.

Even if Radient files for bankruptcy some day, it won't be a press release or an article. It will just be an SEC filing.

Nobody is going to release a PR or write an article if/when Radient gets the patent application approved. It's not news. They have a patent now that will expire in July, and Radient failed despite that patent. A patent renewal won't save this company.

A renewal of the patent will accomplish one thing, I suppose: It would force UNI to keep paying $100,000 per year to manufacture and sell DR-70. If the new patent is rejected, they could terminate their agreement with Radient.